ClinicalTrials.gg
Not yet recruitingNCT07766759Updated Aug 14, 2026

A Phase 1 Study of FXR0906 in Healthy Adults With or Without Elevated Triglycerides

A Phase 1 interventional study of Intervention1: FXR0906 injection and Intervention2: FXR0906 injection in Healthy Adult Volunteers, sponsored by Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd. (part of Fosun Pharma) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics effects of a single dose of FXR0906 injection or placebo in Chinese healthy adult volunteers with or without TG increase.

Read the detailed description

This phase 1 study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single dose of FXR0906 injection in healthy adults with or without TG increase. Eligible enrolled participants will be randomized to 3 groups receiving FXR0906 (dose 1 or dose 2) or placebo on Day 1 and will be followed up for about 26 weeks

02

Conditions studied

  • Healthy Adult Volunteers
03

In context

Lead sponsor

Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion criteria:

1. Males or females aged ≥18 and ≤55 years at the time of screening; 2. (BMI) ≥18.0 and ≤35.0 kg/m² at the time of screening, with female participants weighing >45 kg and male participants weighing >50 kg; 3. Fasting serum triglyceride (TG) level TG > 80 mg/dL (0.90 mmol/L) during screening; 4. Fasting LDL-C level ≥ 70 mg/dL (1.81 mmol/L) during screening; Exclusion criteria: 1. History or presence of diseases/abnormality, or with clinically significant symptoms/signs, or self-reported diseases, unsuitable for enrollement in the judgement of the investigator.

2. Fasting blood glucose ≥7.0 mmol/L or ≥6.5% during screening. 3. Use of any lipid-lowering treatment (e.g., drugs lowering LDL-C or TG), including but not limited to statins, ezetimibe, fibrates, omega-3 fatty acids, nutritional supplements, or other treatment regimens altering serum lipids within 30 days prior to screening, or use of any ASO or siRNA therapies lowering serum lipids within 12 months prior to screening..

4. Use of drugs or instruments within 3 months prior to screening , or plans to participate in other clinical trials during this study. 5. Clinical laboratory parameters during screening meeting any of the following criteria:

  1. and/or AST >1.5 ×
  2. ALT and/or AST > ULN and ≤1.5 × ULN, deemed clinically significant and unsuitable for participation in the clinical trial by the investigator
  3. > ULN, deemed clinically significant and unsuitable for participation in the clinical trial by the investigator
  4. Estimated (eGFR) \<90 mL/min/1.73 m2 (using MDRD formula)
  5. Other examination abnormalities deemed clinically significant and unsuitable for participation in the clinical trial by the investigator
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Arm1: FXR0906 injection

    Dose 1 of FXR0906 injection

    Drug: Intervention1: FXR0906 injection

  • Experimental
    Arm2: FXR0906 injection

    dose 2 of FXR0906 injection

    Drug: Intervention2: FXR0906 injection

  • Placebo comparator
    Arm3: placebo comparator: placebo

    placebo

    Drug: Placebo

Interventions

  • DrugIntervention1: FXR0906 injection

    A single dose of FXR0906 (dose 1 ) will be administered on Day 1 by subcutaneous injection

  • DrugIntervention2: FXR0906 injection

    A single dose of FXR0906 (dose 2) will be administered on Day 1 by subcutaneous injection

  • DrugPlacebo

    the volume mached placebo is normal saline (0.9%) and will be administered on Day 1.

06

What researchers measure

Primary outcomes

  1. safety

    the incidence, frequency, and severity of adverse events (AEs) and serious adverse events (SAEs), and the relationship with FXR0906

    Time frame: through study completion, an average of 26 weeks

Secondary outcomes

  1. peak concentration (Cmax)

    PK parameters

    Time frame: Day0-Day3 ( Predose ~ post-dose 48h)

  2. time to peak (Tmax)

    PK parameter

    Time frame: Day0-Day3 ( Predose ~ post-dose 48h)

  3. area under the blood drug concentration-time curve from 0 to 24 hours (AUC0-24)

    PK parameter

    Time frame: Day0-Day3 ( Predose ~ post-dose 48h)

  4. area under the blood drug concentration-time curve from 0 to the last measurable blood drug concentration time t (AUC0-t)

    PK parameter

    Time frame: Day0-Day3 ( Predose ~ post-dose 48h)

  5. area under the blood drug concentration-time curve from 0 to infinity (AUC0-inf)

    PK parameter

    Time frame: Day0-Day3 ( Predose ~ post-dose 48h)

  6. terminal elimination rate constant (λz)

    PK parameter

    Time frame: Day0-Day3 ( Predose ~ post-dose 48h)

  7. elimination half-life (t1/2)

    PK parameter

    Time frame: Day0-Day3 ( Predose ~ post-dose 48h)

  8. apparent clearance (CL/F)

    PK parameter

    Time frame: Day0-Day3 ( Predose ~ post-dose 48h)

  9. apparent volume of distribution (Vz/F)

    PK parameter

    Time frame: Day0-Day3 ( Predose ~ post-dose 48h)

  10. Pharmacodynamic (PD) parameters

    This investigation will assess the changes in fasting serum APOC3 and triglyceride (TG) levels over time

    Time frame: through study completion, an average of 26 weeks

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Sep 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2026
First posted
Aug 14, 2026
StartEst.
Aug 25, 2026
Primary completionEst.
Sep 24, 2027
CompletionEst.
Dec 20, 2027
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07766759
Responsible party
Sponsor
First posted
Aug 14, 2026
Start date
Aug 25, 2026 (estimated)
Primary completion
Sep 24, 2027 (estimated)
Completion
Dec 20, 2027 (estimated)
Last update
Aug 14, 2026

Study contacts

Yida Tang, PhD
Contact
tang_yida@163.com
+86 13901010211
Yu Fu
Contact
lilac_fu@163.com
+86 13671185050

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion